C/EBPα overexpression overrides epigenetic reprogramming by RUNX1-ETO and RUNX1-EVI1
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
应用场景：
创建时间：
2021-07-25
相关数据集
Table 5_Local Promoter Methylation Disorder algorithm reveals bidirectional epigenetic disruption in DNMT3A-mutated AML and predicts azacitidine treatment response.xlsx
BackgroundDNMT3A mutations occur in 20-25% of acute myeloid leukemia (AML) cases and are associated with poor prognosis, yet the epigenetic mechanisms underlying treatment response remain poorly under
NIAID Data Ecosystem80
Supplementary Table 7 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
GO Analysis from Regions of Differential MOLM13 H3K27Ac CUT&Tag (6 Hours After Drug Treatment) Pileup at Enhancers and Promoters
NIAID Data Ecosystem50
AMPK links acetyl-coA homeostasis to BET recruitment in acute myeloid leukemia: ChIP-seq
Altered metabolism fuels two hallmark properties of cancer cells, unlimited proliferation and differentiation blockade. AMP-activated protein kinase (AMPK) is a master regulator of bioenergetics cruci
NIAID Data Ecosystem40
Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [anti-H3K9 ac, anti-H3K27, RCOR1, SPI1, and MLL4 ChIP-Seq]. Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [anti-H3K9 ac, anti-H3K27, RCOR1, SPI1, and MLL4 ChIP-Seq]
To determine whether changes in histone modifications directly correlate with changes in transcription, THP1 AML cells were treated with a potent and selective LSD1 inhibitor (OG86, 250nM) and then su
NIAID Data Ecosystem60
H3K9 acetylation and di-methylation changes in HL-60 cells following treatment with different compounds. H3K9 acetylation and di-methylation changes in HL-60 cells following treatment with different compounds
We investigate the effects of GCN5 and LSD1 inhibition in acute myeloid leukemia. Therefore, we characterized acetylation and di-methylation changes by ChIP-seq in AML cells (AML M2 cell line HL-60) f
NIAID Data Ecosystem50
